Table 1 Characteristics of study participants. Distribution of demographic and clinicopathological variables of overall breast cancer patients and the characteristics by tumor subtypes

Age (year old)

1304 (100%)

592 (45.4%)

159 (12.2%)

210 (16.1%)

343 (26.3%)

Mean (range)

50.9 (23.90)

51.5 (27.90)

49 (30.72)

51 (24.78)

50.6 (23.83)

≤ 35

85 (6.5%)

33 (5.6%)

12 (7.5%)

15 (7.2%)

25 (7.3%)

0.059

36–40

148 (11.4%)

49 (8.3%)

24 (15.1%)

22 (10.1%)

53 (15.5%)

41–55

637 (48.8%)

312 (52.7%)

75 (47.2%)

103 (49.8%)

147 (42.9%)

56–65

333 (25.6%)

150 (25.3%)

39 (24.5%)

56 (26.6%)

88 (25.6%)

> 65

101 (7.7%)

48 (8.1%)

9 (5.7%)

14 (6.3%)

30 (8.7%)

Ethnicity

Javanese

1273 (97.6%)

578 (97.6%)

156 (98.1%)

206 (98.1%)

333 (97.1%)

0.808

Non-Javanese

31 (2.4%)

14 (2.4%)

3 (1.9%)

4 (1.9%)

10 (2.9%)

Menarche (year old)

≤ 12

225 (17.3%)

90 (15.2%)

25 (15.7%)

39 (18.6%)

71 (20.7%)

0.369

13–14

605 (46.4%)

275 (46.5%)

77 (48.4%)

94 (44.8%)

159 (46.4%)

≥ 15

474 (36.3%)

227 (38.3%)

57 (38.5%)

77 (36.7%)

113 (32.9%)

Menopause age (year old)

≤ 50

715 (76%)

356 (79.6%)

75 (70%)

114 (72.2%)

170 (73.6%)

0.009

> 50

226 (24%)

91 (20.4%)

31 (30%)

43 (27.8%)

61 (26.4%)

Parity

Nulliparous

138 (10.6%)

62 (10.5%)

23 (14.5%)

17 (8.2%)

36 (10.5%)

0.288

Multiparous

1166 (89.4%)

530 (89.5%)

136 (85.5%)

193 (91.8%)

307 (89.5%)

Breastfeeding

No

252 (19.3%)

120 (20.3%)

34 (21.4%)

34 (16.4%)

64 (18.7%)

0.576

Yes

1052 (80.7%)

472 (79.7%)

125 (78.6%)

176 (83.6%)

279 (81.3%)

BMI

≤ 18.5

172 (13.2%)

80 (13.5%)

23 (14.5%)

28 (13.3%)

41 (12.0%)

0.956

18.5–25

661 (50.7%)

298 (48.3%)

76 (47.8%)

109 (51.9%)

178 (51.9%)

25–30

348 (26.7%)

158 (27.9%)

48 (30.2%)

54 (25.7%)

88 (25.7%)

> 30

123 (9.4%)

56 (10.3%)

12 (7.5%)

19 (9.0%)

36 (10.5%)

Family history

Yes

234 (17.9%)

98 (16.6%)

27 (17%)

44 (21.0%)

65 (19%)

0.449

No

1070 (82.1%)

494 (83.4%)

132 (83%)

166 (79.0%)

278 (81%)

Histology grade

I

8 (0.7%)

3 (0.5%)

2 (1.3%)

0 (0%)

3 (0.9%)

0.411

II

247 (18.9%)

122 (20.6%)

29 (18.2%)

38 (18.1%)

58 (16.9%)

III

1049 (80.4%)

467 (78.9%)

128 (80.5%)

172 (81.9%)

282 (82.2%)

Stage

I

11 (0.9%)

6 (1%)

1 (0.6%)

2 (1%)

2 (0.6%)

0.005

II

343 (26.3%)

187 (31.6%)

31 (19.5%)

50 (23.8%)

75 (21.9%)

III

705 (54.2%)

292 (49.3%)

90 (56.6%)

118 (56.2%)

205 (59.8%)

IV

245 (18.8%)

107 (18.1%)

37 (23.3%)

40 (19.0%)

61 (17.8%)

Tumor size

≤ 2 cm

57 (4.3%)

31 (5.3%)

7 (4.4%)

10 (4.8%)

9 (2.6%)

0.077

2–5 cm

345 (26.5%)

169 (28.5%)

39 (24.5%)

58 (27.6%)

79 (23%)

> 5 cm

902 (69.2%)

392 (66.2%)

113 (71.1%)

142 (67.6%)

255 (74.4%)

Node status

N0

308 (23.6%)

161 (27.2%)

28 (17.6%)

46 (21.9%)

73 (21.3%)

0.054

N1

687 (52.7%)

312 (52.7%)

84 (52.8%)

106 (50.5%)

185 (53.9%)

N2

250 (19.2%)

92 (15.5%)

38 (23.9%)

47 (22.4%)

73 (21.3%)

N3

59 (4.5%)

27 (4.6%

9 (5.7%)

11 (5.2%)

12 (3.5%)

Endocrine therapy

No

555 (42.6%)

11 (1.9%)

1 (0.6%)

206 (98.1%)

337 (98.3%)

0.118

Tamoxifen

389 (29.8%)

294 (49.7%)

87 (54.7%)

2 (1%)

6 (1.7%)

Aromatase inhibitor

360 (27.6%)

287 (48.5%)

71 (44.7%)

2 (1%)

0 (0%)

Chemotherapy

No

203 (15.6%)

91 (15.4%)

21 (13.2%)

35 (16.7%)

56 (16.3%)

0.772

Yes

1101 (84.6%)

501 (84.6%)

138 (86.8%)

175 (83.3%)

287 (83.7%)

Radiotherapy

No

490 (37.6%)

225 (38%)

60 (37.7%)

89 (42.4%)

116 (33.8%)

0.118

Yes

814 (62.4%)

367 (62%)

99 (62.3%)

121 (57.6%)

227 (66.2%)

Surgery

Mastectomy

1069 (82%)

473 (79%)

124 (78%)

180 (85.7%)

292 (85.1%)

0.172

BCT

99 (7.6%)

49 (8.3%)

13 (8.2%)

14 (6.7%)

23 (6.7%)

Biopsy

136 (10.5%)

70 (11.8%)

22 (13.8%)

16 (7.6%)

28 (8.2%)